History of methysergide in migraine

Cephalalgia

Volumn 28, Issue 11, 2008, Pages 1126-1135

  Koehler, P J ^a   Tfelt Hansen, P C ^b,c  

^a Sittard Geleen Heerlen   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

5 HT antagonist; 5 hydroxytryptamine; Methylergometrine; Methysergide; Migraine

Indexed keywords

BROMOCRIPTINE; BUTOLAMIDE; CARBIDOPA; DIHYDROERGOTOXINE MESILATE; ERGOMETRINE; ERGOTAMINE; LYSERGIC ACID; LYSERGIDE; METHYL GROUP; METHYLDOPA; METHYLERGOMETRINE; METHYSERGIDE; METHYSERGIDE MALEATE; PLACEBO; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; CLUSTER HEADACHE; DEMETHYLATION; DIZZINESS; DROWSINESS; DRUG ELIMINATION; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; EPIGASTRIC PAIN; HEART MUSCLE FIBROSIS; HUMAN; LEG CRAMP; LUNG FIBROSIS; MIGRAINE; NAUSEA; NOCICEPTION; NONHUMAN; PAIN THRESHOLD; PROPHYLAXIS; RETROPERITONEAL FIBROSIS; REVIEW; SIDE EFFECT; WEAKNESS; WEIGHT GAIN;

ANIMALS; HISTORY, 20TH CENTURY; HUMANS; METHYSERGIDE; MIGRAINE DISORDERS; SEROTONIN ANTAGONISTS;

EID: 53549088309     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2008.01648.x     Document Type: Review

References (71)

1. Woakes E. On ergot of rye in the treatment of neuralgia. BMJ 1868 II : 360 1.
2. Koehler PJ, Isler H. The early use of ergotamine in migraine. Edward Woakes' report of 1868, its theoretical and practical background, and its international reception. Cephalalgia 2002 22 : 686 91.
3. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and forward. Cephalalgia (in press).
4. Rooke ED, Rushton JG, Peters GA. Vasodilating headache: a suggested classification and results of prophylactic treatment with UML491 (methysergide). Proc Staff Meet Mayo Clin 1962 37 : 433 43.
5. Rapport MM, Green AA, Page H. Partial purification of the vasoconstrictor in beef serum. J Biol Chem 1948 174 : 735 8.
6. Sjoerdsma A, Palfreyman MG. The neuropharmacology of serotonin. History of serotonin and serotonin disorders. Ann NY Acad Sci 1990 600 : 1 8.
7. Twarog BM. Serotonin: history of a discovery. Comp Biochem Physiol 1988 91 : 21 4.
8. 3H]spiroperidol. Mol Pharmacol 1979 16 : 687 99.
9. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann NY Acad Sci 1990 600 : 587 98.
10. Wolff HG, Tunis MM, Goodell H. Studies on headache. Evidence of tissue damage and changes in pain sensitivity in subjects with vascular headaches of the migraine type. Arch Intern Med 1953 92 : 478 84.
11. Ostfeld AM, Chapman LF, Goodell H, Wolff HG. Studies in headache. Summary of evidence concerning a noxious agent active locally during migraine headache. Psychosomat Med 1957 19 : 199 208.
12. Wolff HG, Ostfeld AM, Chapman LF, Goodell H. Studies in headache: a summary of evidence implicating a locally active chemical agent in migraine. Trans Amer Neurol Ass 81st meeting, 1956, p. 356.
13. Harris MC. Serotonin. Its possible relation to allergic diseases. Calif Med 1959 91 : 68 71.
14. Ostfeld AM. Migraine headache. Its physiology and biochemistry. JAMA 1960 174 : 1188 90.
15. Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in hydroxyindolacetic acid excretion during migraine attacks. Int Arch Allergy 1961 19 : 55 8.
16. Curran DA, Hinterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 1965 88 : 997 1007.
17. Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967 16 : 544 52.
18. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 1960 10 : 107 11.
19. Doepfner W, Cerletti A. Comparison of lysergic acid derivatives and antihistamines as inhibitors of the oedema provoked in the rat's paw by serotonin. Int Arch Allergy 1958 12 : 89.
20. Fanchamps A, Doepfner W, Weidman H, Cerletti A. Pharmakologische Characterisierung von Deseril, einem Serotonin-Antagonisten. Schweiz Med Wochenshr 1960 90 : 1040 6.
21. Sicuteri F. Prophylactic and therapeutic properties of 1-methyllysergic acid butanolamide in migraine. Int Arch Allerg 1959 15 : 300 7.
22. Greppi E, Sicuteri F. Fattori allergici su terreno emicranico. Folia Allergol 1955 2 : 164.
23. Heyck H. Serotoninantagonisten in der Behandlung der Migräne und der Erythroprosopalgie Bings oder des Horton-Syndroms. Schweiz Med Wochenschr 1960 90 : 203 9.
24. Graham JR. Use of new compound, UML-491. (l-methyl-D-lysergic acid butanolamide), in prevention of various types of headache; pilot study. N Engl J Med 1960 263 : 1273 7.
25. Friedman AP, Losin S. Evaluation of UML-491 in the treatment of vascular headaches. An analysis of the effects of 1-methyl-D-lysergic acid (plus) butanolamide bimaleate (methysergide). Arch Neurol 1961 4 : 241 5.
26. Harris MC. Prophylactic treatment of migraine headache and histamine cephalalgia with a serotonin antagonist (methysergide). Ann Allergy 1961 19 : 500 4.
27. Hale AR, Reed AF. Prophylaxis of frequent vascular headache with methysergide. Am J Med Sci 1962 243 52.
28. Abbott KH. Clinical studies on the treatment of vascular headache. Bull Los Angeles Neurol Soc 1962 27 : 137 46.
29. Southwell N, Williams JD, Mackenzie I. Methysergide in the prophylaxis of migraine. Lancet 1964 I : 523 4.
30. Ad Hoc Committee on Classification of Headache. Classification of headache. JAMA 1962 179 : 127 718.
31. Pedersen E, Moller CE. Methysergide in migraine prophylaxis. Clin Pharmacol Ther 1966 7 : 520 6.
32. Friedman AQ, Elkind AH. Appraisal of methysergide in treatment of vascular headaches of the migraine type. JAMA 1963 184 : 125 8.
33. Dalsgaard-Nielsen T. Preventive therapy of migraine with Deseril. Ugeskr Laeger 1964 126 : 1358 9.
34. Friedman AP. Clinical observations with 1-methyl-lysergic acid butanolamide (UML-491) in vascular headache. Angiology 1960 11 : 364 6.
35. Graham JR. Methysergide for prevention of migraine. N Engl J Med 1964 270 : 67 72.
36. Silberstein SD. Methysergide. Cephalalgia 1998 18 : 421 35.
37. Utz DZ, Rooke ED, Spittell JA Jr., Bartholomew LG. Retroperitoneal fibrosis in patients taking methysergide. JAMA 1965 191 : 983 5.
38. Graham JR, Suby HI, LeCompte PR, Sadowski NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966 274 : 359 68.
39. Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 1967 254 : 1 12.
40. Bianchine JR, Friedman AP. Metabolism of methysergide and retroperitoneal fibrosis. Arch Intern Med 1970 126 : 252 6.
41. Tfelt-Hansen P, Saxena PR. Antiserotonin drugs in migraine prophylaxis. In : Olesen J, Tfelt-Hansen P, Goadsby PJ, Ramadan NM, Welch KMA, eds. The headaches, 3rd edn. Philadelphia, PA : Lippincott Williams & Wilkins 2006 : 529 37.
42. Berde B, Schild HO, eds. Ergot alkaloids and related compounds. Handbook of experimental pharmacology, Vol. 49. Berlin, New York : Springer-Verlag 1978.
43. Bianchine JR. Metabolism of methysergide (MS) in the rabbit and man. Fed Proc 1968 27 : 238.
44. Bredberg U, Eyjolfsdottir GS, Paalzow L, Tfelt-Hansen P, Tfelt-Hansen V. Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Eur J Clin Pharmacol 1986 30 : 75 7.
45. Tfelt-Hansen P, Jansen I, Edvinsson L. Methylergometrine antagonises 5-HT in the temporal artery. Eur J Clin Pharmacol 1987 33 : 77 9.
46. Saito K, Markowitz S, Moskowitz MA. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 1988 27 : 732 7.
47. Dalessio DJ. Recent experimental studies on headache. Neurology 1963 13 : 7 10.
48. Saxena PR. Selective carotid vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine action. Eur J Pharmacol 1974 27 : 99 105.
49. Fanciullacci M, Granchi G, Sicuteri F. Ergotamine and methysergide as serotonin partial agonists in migraine. Headache 1976 16 : 226 31.
50. Feniuk W, Humphrey PP, Watts AD. Modification of the vasomotor action of methysergide in the femoral arterial of the anaesthetized dog by changes in sympathetic nerve activity. J Autonom Pharmacol 1981 1 : 127 32.
51. Watts AD, Feniuk W, Humphrey PP. A pre-junctional action of 5-hydroxytryptamine and methysergide on noradrenergic nerves in dog isolated saphenous vein. J Pharm Pharmacol 1981 33 : 515 20.
52. Saxena PR, Verdouw PD. Effects of methysergide and 5-hydroxytryptamine on carotid blood flow distribution in pigs: further evidence for the presence of atypical 5-HT receptors. Br J Pharmacol 1984 82 : 817 26.
53. Humphrey PP. The discovery of a new drug class for the acute treatment of migraine. Headache 2007 47 (Suppl. 1 S10 19.
54. Humphrey PP, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991 12 : 444 6.
55. Mylecharane EJ. 5-HT2 receptor antagonists and migraine therapy. J Neurol 1991 238 (Suppl. 1 S45 52.
56. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006 59 : 652 61.
57. Olesen J, Goadsby PJ, Ramadan N, Tfelt-Hansen P, Welch KMA, eds. The headaches, 3rd edn. Philadelphia, PA : Lippincott, Williams and Wilkins 2006.
58. Schoonman GG, Evers DJ, Terwindt GM, van Dijk JG, Ferrari MD. The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia 2006 26 : 1209 13.
59. Roon KI, Van M, Brink A, Ferrari MD, Saxena PR. Bovine isolated middle cerebral artery contractions to antimigraine drugs. Naunyn Schmiedebergs Arch Pharmacol 1999 360 : 591 6.
60. Van M, Brink A, Reekers M, Bax WA, Ferrari MD, Ferrari PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998 98 : 25 30.
61. Monstad I, Krabbe A, Micieli G, Prusinski A, Cole J, Pilgrim A, Shevlin P. Preemptive oral treatment with sumatriptan during a cluster period. Headache 1995 35 : 607 13.
62. Diener HC, Silberstein SD. Medication overuse headache. In : Olesen J, Tfelt-Hansen P, Goadsby PJ, Ramadan NM, Welch KMA, eds. The headaches, 3rd edn. Philadelphia, PA : Lippincott Williams & Wilkins 2006 : 971 9.
63. Bergerot A, Storer RJ, Goadsby PJ. Dopamine inhibits trigeminovascular transmission in the rat. Ann Neurol 2007 61 : 251 62.
64. Fanciullacci M, Allesandrini M, Del Rosso A. Dopamine involvement in the migraine attack. Funct Neurol 2000 15 (Suppl. 3 171 81.
65. Cerbo R, Barbanti P, Buzzi MG, Fabbrini G, Brusa L, Roberti C et al. Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin Neuropharmacol 1997 20 : 36 41.
66. Kim YC, Hayase M, Nakomura E, Kito Y, Suzuki H. Effects of 5-hydroxytryptamine on electrical responses of circular smooth muscle isolated from the guinea-pig gastric atrium. J Smooth Muscle Res 2006 42 : 203 16.
67. Lima C, Souza VM, Soaves AL, Macebo MS, Tavares-de-Lima W, Vargaftig BB. Interference of methysergide, a specific 5-hydroxytryptamine receptor antagonist, with airway chronic allergic inflammation and remodelling in a murine model of asthma. Clin Exp Allergy 2007 37 : 723 34.
68. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994 46 : 157 203.
69. Edvinsson L, Jansen I, Olesen J. Characterization of human craniovascular 5-hydroxytryptamine receptors. In : Olesen J, Saxena PR, eds. 5-Hydroxytryptamine mechanisms in primary headaches. New York : Ravens Press 1992 : 129 36.
70. Lance JW, Fine RD, Curran DA. An evaluation of methysergide in the prevention of migraine and other vascular headache. Med J Aust 1963 1 : 814 18.
71. Pichler E, Szlemkewycz M. Neurologic indication of Deseril. Wien Z Nervenheilkd Grenzgeb 1963 21 : 186 90.